de
Monthly Overview
Quarterly Overview
Largest Investments
Private Companies
Specialised Venture Capital Funds
Public Companies
Public Companies as at 30.6.2010
Basilea Pharmaceutica
China Nuokang
Micrus Endovascular
SkyePharma
Swedish Orphan Biovitrum
For details on investments in public companies, please click
here:
News
Press Releases
»
HBM BioVentures Quarterly Report as at 30 June 2010
»
HBM BioVentures’ largest public investment – Micrus – acquired
by Johnson & Johnson
»
HBM BioVentures sells USD hedging position at a profit
»
Shareholders’ meeting approves all proposals by Board of Directors by large majority; Hans Peter Hasler appointed as new Chairman of the Board of Directors; Astellas, which recently acquired OSI Pharmaceuticals, will retain HBM BioVentures shares and intensify cooperation
»
Archive
Financial Reports
»
Quarterly Report June 2010
»
Annual Report 2009/2010
»
Archive
Share Price
SIX Swiss Exchange Ticker
HBMN
Key Figures
as at 31.8.2010
CHF
NAV
per share
62.58
Net assets
616 Mio.
Search
News Registration
Sign up now